[SCHEDULE 13G] MediWound Ltd. SEC Filing

Rhea-AI Filing Summary

HOLD Alapkezelo Zrt. filed a Schedule 13G reporting beneficial ownership of 703,429 common shares of MediWound Ltd., representing approximately 6.52% of the outstanding common stock based on 10,793,057 shares outstanding as of December 31, 2024. The filer is a Hungarian investment fund management company (not SEC-registered) with sole voting and dispositive power over the reported shares. The filing states the shares were not acquired to influence control of the issuer. MediWound's principal executive offices are listed in Yavne, Israel.

Positive

• Reported stake exceeds 5%, triggering disclosure: 703,429 shares (~6.52%) which provides transparency to investors
• Sole voting and dispositive power is clearly stated, removing ambiguity about who exercises authority over the shares
• Filer certifies passive intent (shares not acquired to influence control), which clarifies the reported purpose

Negative

• None.

Insights

Financial Analyst

TL;DR: A non‑U.S. investment manager reports a >5% passive stake in MediWound, notable but declared non‑control.

The filing shows HOLD Alapkezelo Zrt. holds 703,429 shares, ~6.52% of common stock based on the issuer's 10,793,057 shares outstanding as of December 31, 2024. For investors, a >5% stake from an institutional investor is material because it can signal interest or increased monitoring of the company; however, the filer explicitly certifies the stake is not for influencing control and reports sole voting and dispositive power over the shares. No transaction timing, accumulation strategy, or coordination with others is disclosed.

Corporate Governance Expert

TL;DR: Ownership crosses the 5% reporting threshold but the filer declares a passive intent, implying no immediate governance change.

Crossing the 5% threshold triggers public disclosure requirements and can attract attention from management and other shareholders. HOLD Alapkezelo Zrt. classifies itself as a Hungarian investment manager and confirms the securities were not acquired to influence control. The filing contains standard certifications and does not identify any group affiliation or shared voting arrangements, which supports a governance stance of non‑coordination. No board nominations or control‑seeking activities are indicated.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MediWound Ltd.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

M68830104

(CUSIP Number)

09/22/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M68830104

1

Names of Reporting Persons

HOLD Alapkezelo Zrt.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

HUNGARY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 703,429.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 703,429.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

703,429.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Hungarian investment fund management company without SEC registration.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MediWound Ltd.
(b)	Address of issuer's principal executive offices: 42 HAYARKON STREET, YAVNE, ISRAEL, 8122745
Item 2.
(a)	Name of person filing: HOLD Alapkezelo Zrt. (HUNGARY)
(b)	Address or principal business office or, if none, residence: H-1123 Budapest, Alkotas u. 50., Hungary
(c)	Citizenship: Hungarian
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: M68830104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Based upon 10,793,057 shares of the Issuers common stock outstanding as of December 31, 2024, in accordance with 20F filed on March 19, 2025. HOLD Alapkezelo Zrt. may have been deemed to have the beneficial ownership of 703,429 shares of common stock representing the beneficial ownership of approximately 6.52% of the common stocks.
(b)	Percent of class: HOLD Alapkezelo Zrt: 6.52%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: HOLD Alapkezelo Zrt.: 703,429 shares of Common Stock
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: HOLD Alapkezelo Zrt.: 703,429 shares of Common Stock
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

HOLD Alapkezelo Zrt.

Signature:	Daniel Moricz
Name/Title:	Chief Investment Officer, Partner
Date:	09/19/2025

FAQ

How many MediWound (MDWD) shares does HOLD Alapkezelo Zrt. report owning?

The filing reports 703,429 shares of MediWound common stock.

What percentage of MDWD does HOLD Alapkezelo Zrt.'s stake represent?

The reported stake represents approximately 6.52% of the outstanding common stock based on 10,793,057 shares outstanding as of December 31, 2024.

Was the reported stake filed as active or passive under Schedule 13G?

The filer certifies the securities were not acquired to influence control and therefore is reporting under the passive Schedule 13G framework.

Does HOLD Alapkezelo Zrt. share voting or dispositive power over these MDWD shares?

No; the filing states sole voting power and sole dispositive power over the 703,429 shares, with no shared powers reported.

Where are MediWound's principal executive offices listed in the filing?

The filing lists the issuer's principal executive offices at 42 Hayarkon Street, Yavne, Israel, 8122745.